Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Idiopathic pulmonary fibrosis urine protein marker, and application of same to diagnosis and prognosis

A pulmonary fibrosis and fibrin technology, which is applied in the field of clinical medicine, can solve problems such as affecting the quality of life of patients, the pathogenesis of pulmonary fibrosis is not completely clear, and the treatment effect is not good.

Active Publication Date: 2017-02-01
BEIJING NORMAL UNIVERSITY
View PDF2 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At the same time, the pathogenesis of pulmonary fibrosis is not yet fully understood, and most of the patients who seek treatment are in the middle and late stages of the disease, and the treatment effect is not good, which seriously affects the quality of life of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Idiopathic pulmonary fibrosis urine protein marker, and application of same to diagnosis and prognosis
  • Idiopathic pulmonary fibrosis urine protein marker, and application of same to diagnosis and prognosis
  • Idiopathic pulmonary fibrosis urine protein marker, and application of same to diagnosis and prognosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Example 1. Establishment of an animal model of idiopathic pulmonary fibrosis

[0061] 1. The bleomycin-induced pulmonary fibrosis rat model is a classic animal model of idiopathic pulmonary fibrosis, which has been used to study the pathogenesis of pulmonary fibrosis, develop anti-fibrosis drugs, and test drug efficacy (see Kulkarni Y M , Dutta S, Iyer A K V et al., A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin‐induced pulmonary fibrosis. Proteomics, 2016, 16(1):33-46).

[0062] Use this animal model to simulate the pathogenesis of pulmonary fibrosis, observe the overall changes of pulmonary fibrosis from normal, early fibrosis, fibrosis progression and fibrosis treatment, which is helpful for early diagnosis of pulmonary fibrosis and monitoring the progress of pulmonary fibrosis in clinical practice , Evaluating the therapeutic effect of pulmonary fibrosis has important guiding significance.

[0063...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an idiopathic pulmonary fibrosis urine protein marker, and application of the same to diagnosis and prognosis. Specifically, the invention relates to application of a urine protein marker obtained by using an idiopathic pulmonary fibrosis model and mass spectrometry to early-stage diagnosis, pathogenesis monitoring and curative effect assessment of human pulmonary fibrosis. The urine protein marker comprises collagen alpha-1(I) chain, vimentin, protein RUFY3, keratin type-II skeleton 8, a sodium-hydrogen exchange regulation factor NHE-RF2, a threonine synthase sample 2, zinc-actin binding repeat protein 2, low-density lipoprotein receptor-associated protein 4, alpha-11 of a guanine nucleotide binding protein subunit, an alpha-1 chain of tropomyosin, mitochondrial stress-70 protein, NSFL1 cofactor P47, ubiquitin carboxyl-terminal hydrolase isozyme L1, etc.

Description

technical field [0001] The present invention relates to clinical medicine; in particular, it relates to urine protein markers related to human pulmonary fibrosis. Specifically, the present invention relates to the use of urine protein markers related to the diagnosis, condition monitoring and curative effect evaluation of human pulmonary fibrosis obtained by using the pulmonary fibrosis rat disease model and mass spectrometry proteomics technology. Background technique [0002] Urine proteomics is of great significance in the study of disease markers. Biomarkers are monitorable changes associated with pathophysiological processes, which can be used to diagnose diseases, monitor disease processes, predict disease prognosis, and evaluate treatment effects, etc. [0003] Urine is an ideal source of biomarkers and can be obtained in large quantities noninvasively. Compared with other body fluids, urine has a low background value and stable protein has a smaller dynamic range. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68G01N33/577G01N33/531G01N33/532G01N30/02G01N30/72
CPCG01N30/02G01N30/72G01N33/531G01N33/532G01N33/577G01N33/6893
Inventor 高友鹤吴建强李逊斗
Owner BEIJING NORMAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com